4//SEC Filing
Arno Therapeutics, Inc 4
Accession 0000914190-16-000824
CIK 0001195116operating
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 4:02 PM ET
Size
14.4 KB
Accession
0000914190-16-000824
Insider Transaction Report
Form 4
SUSSMAN S DONALD
10% OwnerOther
Transactions
- Purchase
Common Stock
2016-08-15+714,285→ 714,285 total - Purchase
2016 Series F Warrants (right to buy)
2016-08-15+357,142→ 357,142 totalExercise: $0.44From: 2016-08-15Exp: 2021-08-15→ Common Stock (357,142 underlying)
Holdings
- 1,523,207(indirect: By LLC)
2013 Series D Warrants
Exercise: $1.81From: 2013-10-29Exp: 2018-10-29→ Common Stock (1,523,207 underlying) - 4,472,905(indirect: By LLC)
Common Stock
- 1,780,625(indirect: By LLC)
2012 Series A Warrants
Exercise: $1.17From: 2013-10-29Exp: 2017-11-26→ Common Stock (1,780,625 underlying)
Footnotes (4)
- [F1]CSC has a contractual right to designate one member of the Issuer's board of directors and has designated Steven B. Ruchefsky, a director of the Issuer, pursuant to such right. Accordingly, the Reporting Person, as a co-managing director of CSC, may be deemed to be a director by deputization for purposes of Section 16 of the Exchange Act.
- [F2]The reported securities are included within 714,285 Issuer units purchased by the Reporting Person for $0.35 per unit. Each unit consists of one share of common stock and a 2016 Series F Warrant to purchase one-half share of common stock.
- [F3]Represents securities of the Issuer directly held by Commercial Street Capital LLC ("CSC"). The Reporting Person is a co-managing member of CSC and as such may be deemed to beneficially own the securities held by CSC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F4]As a result of the Issuer's 8/15/16 private placement of common stock and Series F Warrants, the exercise prices and shares underlying the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected pursuant to anti-dilution adjustment provisions in such warrants.
Issuer
Arno Therapeutics, Inc
CIK 0001195116
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001195116
Filing Metadata
- Form type
- 4
- Filed
- Sep 7, 8:00 PM ET
- Accepted
- Sep 8, 4:02 PM ET
- Size
- 14.4 KB